Janssen Seeks to Expand Darzalex Use for Multiple Myeloma Patients
Janssen Biotech has submitted a supplemental Biologics License…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
In Heavily Treated Myeloma Patients, Selinexor-Dexamethasone Combo Shows Positive Results
Patients with heavily treated multiple myeloma have promising response…
Survival of Younger Myeloma Patients Influenced by Marriage and Insurance, not Ethnicity, Study Finds
With advances in treatment for multiple myeloma, some studies…
Myeloma Patients on Darzalex Combination Treatment Fared Better in Clinical Trial
Adding Darzalex (daratumumab) to the treatment of multiple myeloma…
German Agency Questions Benefit of Empliciti Reported in Multiple Myeloma Study
Empliciti (elotuzumab), a monoclonal antibody, is approved in both the…
Biotech Companies Partner with Memorial Sloan Kettering to Develop Multiple Myeloma Immunotherapy Program
Juno Therapeutics and privately held biotech…
